Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...
The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a ...
From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...
You may feel the urge to pee after you just used the bathroom because of infections, underlying short or long-term health ...
Medpage Today on MSN
First-Line Bladder Cancer Trial Makes the Case for HER2 Screening
The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
HealthDay on MSN
Too Much, Too Little Sleep Tied to Overactive Bladder Risk
(HealthDay News) — The risk for overactive bladder (OAB) is associated with both short and long sleep duration, according to a study published online in Frontiers in Medicine.
Fran Curtis is a five-time survivor of cancers survivor including breast, appendix and skin cancer, but she told CURE in a ...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with ...
MedPage Today on MSN
A Hit and a Miss for Liquid Biopsy to Guide Adjuvant Cancer Therapy
Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...
6d
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the ...
In patients with early-stage HER2-positive breast cancer in the DESTINY-Breast 05 and the DESTINY-Breast 11 trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback